Suppr超能文献

尽快进行 IgE 介导的牛奶过敏免疫治疗。

As soon as possible in IgE-cow's milk allergy immunotherapy.

机构信息

Pediatric Allergy Unit, Miguel Servet University Hospital, Paseo Isabel La Católica 1-3, 50009, Zaragoza, Spain.

Pediatrics, Hospital Universitari Dexeus, Barcelona, Spain.

出版信息

Eur J Pediatr. 2021 Jan;180(1):291-294. doi: 10.1007/s00431-020-03731-3. Epub 2020 Jul 11.

Abstract

Oral immunotherapy is a common treatment in cow's milk protein allergy. The Department of Pediatric Allergology at the Children's Hospital of Zaragoza performed a retrospective analysis of 335 infants under 1 year of age diagnosed with IgE-mediated cow's milk and early treated. Clinical evaluation, skin prick test, and serum-specific IgE level control were performed before starting and after finishing treatment. Upon completion of treatment, more than 98% of patients became tolerant to milk and no one presented serious adverse reactions. Nowadays, the remaining non-tolerant patients (1.8%) can take milk or derivatives daily-as prophylaxis-to a certain maximum dose and still remain asymptomatic. After immunotherapy, both positive skin prick tests and a progressive decrease in specific IgE levels were found, as desensitization to milk increased.Conclusion: Oral immunotherapy is a safe and effective treatment against allergy to cow's milk proteins in infants. Such treatment should be offered to the children's families from the first moment of diagnosis. What is known: • Cow's milk proteins are responsible for the earliest IgE-mediated allergic reactions in children. • Oral immunotherapy (OIT) is commonly used as cow's milk allergy treatment and it is proposed at different ages. What is new: • OIT it is an effective and safe method with no severe reactions at early ages. • The number of reaching successful treatments is awesome so we believe that immunity response can be molded at the first months of life, so the probability of success with infants is greater than in older children.

摘要

口服免疫疗法是治疗牛奶蛋白过敏的常用方法。萨拉戈萨儿童医院的儿科过敏科对 335 名 1 岁以下确诊为 IgE 介导的牛奶过敏并接受早期治疗的婴儿进行了回顾性分析。在开始治疗前和治疗结束后进行临床评估、皮肤点刺试验和血清特异性 IgE 水平控制。治疗完成后,超过 98%的患者对牛奶耐受,没有人出现严重不良反应。如今,仍有 1.8%的非耐受患者(可每日摄入牛奶或奶制品作为预防措施,直至达到一定的最大剂量,并且仍然无症状)。免疫治疗后,发现皮肤点刺试验阳性和特异性 IgE 水平逐渐降低,因为对牛奶的脱敏作用增加。结论:口服免疫疗法是治疗婴儿牛奶蛋白过敏的一种安全有效的方法。应在诊断的第一时间向患儿家属提供这种治疗方法。已知: • 牛奶蛋白是儿童最早发生 IgE 介导的过敏反应的原因。 • 口服免疫疗法(OIT)常用于牛奶过敏的治疗,并在不同年龄段提出。新发现: • OIT 在早期是一种有效且安全的方法,没有严重的反应。 • 达到成功治疗的数量令人瞩目,因此我们相信免疫反应可以在生命的最初几个月形成,因此婴儿成功的可能性大于年龄较大的儿童。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验